IDEAYA Biosciences Inc. Common Stock (IDYA)

FairStock Score: 52/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am wary of businesses that depend on future scientific breakthroughs rather than present profits. IDEAYA is a precision oncology company with only 145 employees, and at the 2026-10-13 close of $34.26 it carries a $3.3B market value. The filed record shows why Graham would demand caution: in fiscal FY2024, revenue was $7.0M and net loss was $274.5M; in FY2025, revenue was $218.7M, but net loss was still $113.7M. That jump was not steady commercial progress—by fiscal Q2 2026, the quarter ended 2026-06-30, revenue was only $8.9M and net loss was $112.5M, or diluted EPS -$1.22. Trailing free cash flow is -$113.9M, and the FairStock calculations show a negative P/E of -17.84, P/B of 2.75, ROE of -16.22%, and ROCE of -11.54%. The balance sheet has low reported debt (D/E 0.02), and Altman Z of 17.30 is a FairStock calculation, but that does not create an earnings moat. Piotroski is 4/9. The Lynch rule puts it in no category because it lost money in each of the last four years. This is a binary clinical-stage story, not a predictable compounding machine. I would want to see durable product revenue, controlled cash burn, and positive owner earnings before calling it a value investment. Price may look fair only if future trials succeed; on today's numbers it looks speculative.

In plain English: IDEAYA is a small biotech company that develops targeted cancer drugs. It is not yet profitable: its latest filed quarter had $8.9 million in revenue and a $112.5 million loss, and it is spending more cash than it brings in. At $34.26, the stock looks expensive compared with current profits because the company still loses money and depends on future drug success.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer